CT-2600

CT-2600 is an investigational drug candidate developed by Circadian Therapeutics, a biotechnology company spun out from the University of Oxford. The drug is being developed for the treatment of neuropsychiatric disorders, targeting the underlying circadian rhythm disruptions that are frequently associated with these conditions. Circadian Therapeutics focuses on identifying and developing small molecule therapies that can reset or stabilize the internal biological clock. While the specific molecular target and modality of CT-2600 have not been publicly disclosed, it is part of a broader pipeline of circadian-modulating assets aimed at addressing unmet needs in neurology and psychiatry.